2.935USD-1.18%Mkt Cap: 535.53M USDP/E: —Last update: 2026-05-26
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap535.53M USD
Enterprise Value511.84M USD
Revenue (TTM)4.03M USD
Gross Profit-150.14M USD
Net Income (TTM)-201.14M USD
Revenue/Share0.0250 USD
Last Price2.935 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees146
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.38
PEG—
EV/EBITDA-2.57
EV/Revenue126.88
P/S132.08
P/B4.32
EPS (TTM)-1.23
EPS (Forward)-0.87
52W Range
1.18030% of range6.940
52W High6.940 USD
52W Low1.180 USD
Profitability
Gross Margin0.00%
Oper. Margin-5917.52%
EBITDA Margin0.00%
Profit Margin-4342.44%
ROE-166.41%
ROA-58.69%
Growth
Revenue Growth-41.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.56M USD
CapEx (TTM)4.53M USD
FCF Margin-1941.44%
FCF Yield-14.62%
Net Debt-20.98M USD
Net Debt/EBITDA0.11
Balance Sheet
Debt/Equity0.96
Current Ratio3.80
Quick Ratio3.73
Book Value/Sh0.6830 USD
Cash/Share0.7500 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)6.917 USD
Target Range4.250 USD – 11.00 USD
# Analysts9
Ownership
Shares Out.180.62M
Float108.73M
Insiders23.76%
Institutions66.46%
Short Interest
Short Ratio16.4d
Short % Float21.51%
Short % Out.16.80%
Shares Short30.35M
Short (prev mo.)29.96M
Technical
SMA 503.465 (-15.3%)
SMA 2003.989 (-26.4%)
Beta2.36
S&P 52W Chg28.31%
Avg Vol (30d)2.19M
Avg Vol (10d)2.66M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—